Dementia-related psychosis readout could lead to label expansion for Acadia's Nuplazid

A new Phase III readout could speed Acadia's timeline to a potential regulatory submission of pimavanserin to treat dementia-related psychosis, an indication that afflicts a much larger population than the one for which the molecule is already approved as Nuplazid.

Acadia Therapeutics

Read the full 414 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE